STROBER, B.; TADA, Y.; MROWIETZ, U.; LEBWOHL, M.; FOLEY, P.; LANGLEY, R. G.; BARKER, J.; WANG, M.; VANVOORDEN, V.; SZILAGYI, B.; CIARAVINO, V.; PAUL, C. Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 6, p. s65, 2022. DOI: 10.25251/skin.6.supp.65. Disponível em: Acesso em: 1 feb. 2023.